Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Hyper Personalized Medicine Market is Expected to Reach $5.9 Trillion by 2031: Allied Market Research

This image opens in the lightbox

News provided by

Allied Market Research

23 Mar, 2023, 09:49 GMT

Share this article

Share toX

Share this article

Share toX

Rising public awareness about hyper personalized medicine, development of efficient and advanced technology, increasing government initiatives around the world, and surging development of genetic databases drive the global hyper personalized medicine market

PORTLAND, Ore., March 23, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Hyper Personalized Medicine Market by Product (Hyper Personalized Medicine Diagnostics, Hyper Personalized Medicine Therapeutics, Hyper Personalized Medical Care, Hyper Personalized Nutrition and Wellness), by Application (Oncology, Neurology, Blood Transfusion Safety, Diabetes, Autoimmune Diseases, Cardiology), by End User (Hospitals, Diagnostic Centers, Research and Academic Institutes, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global hyper personalized medicine industry was valued at $2.1 trillion in 2021 and is estimated to generate $5.9 Trillion by 2031, witnessing a CAGR of 11.7% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chain, regional landscape, and competitive scenario.

Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/32349

Drivers, Restraints, and Opportunities

Rising public awareness about hyper personalized medicine, development of efficient and advanced technology, increasing government initiatives around the world, and surging development of genetic databases drive the global hyper personalized medicine market. However, lack of insurance coverage for genetic testing, which is a required test to detect mutations and prescribe personalized medicines, is a major problem, which is restraining the growth of the global hyper personalized medicine market. Moreover, increase in customized medicine usage in neurology, antiviral medicine, pulmonary medicine, and psychiatry, as well as scope in emerging economies will present new growth opportunities for the global market in the coming years.

Covid-19 Scenario:

  • The COVID-19 pandemic had a mixed impact on the hyper personalized medicine market. The pandemic caused a significant shift in the healthcare business as a whole, with a stronger emphasis on the production and marketing of COVID-19 vaccinations and therapies.
  • The pandemic caused enormous disruptions in the healthcare industry, including delays in drug trials, supply chain disruptions, and reductions in financing for research and development. These factors hampered the product development and marketing of new hyper personalized medicine.
  • There was a rise in interest and investment in personalized medicine as a solution to address people's specific healthcare requirements. As a result, a greater emphasis was placed on the creation of tailored therapies and diagnostic technologies. Many governments launched initiatives to accelerate the use of precision medicine in the treatment of coronavirus.

The hyper personalized nutrition and wellness segment to grab the lion's share during the forecast period

Based on product, the hyper personalized nutrition and wellness segment contributed to the largest share of nearly two-fifths of the global hyper personalized medicine market in 2021 and is expected to maintain its dominance during the forecast period. These services offer personalized nutrition and wellness regimens based on an individual's specific needs and preferences, by utilizing data such as genetic information, lifestyle behavior, and health history. On the other hand, the hyper personalized medicine therapeutics segment is projected to witness the fastest CAGR of 12.2% from 2022 to 2031. Hyper-personalized medicine uses advanced technologies such as genomics, proteomics, and artificial intelligence to design targeted treatments that are customized to an individual patient's specific genetic and molecular features.

Procure Complete Report (220 Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/checkout-final/hyper-personalized-medicine-market 

The oncology segment to dominate the market during the forecast period

Based on application, the oncology segment grabbed the highest share of more than one-fourth of the hyper personalized medicine market in 2021 and is expected to dominate the market in 2031. Also, the same segment would witness the fastest CAGR of 12.8% from 2022 to 2031. The use of modern technology, including genome sequencing and molecular profiling to discover particular genetic mutations and biomarkers that are propelling the growth of a patient's cancer cells is referred to as hyper-personalized oncology.

The hospitals segment grabbed the highest share in 2021

Based on end user, the hospitals segment accounted for the highest share of more than two-fifths of the global hyper personalized medicine market revenue in 2021 and is expected to maintain its dominance during the forecast period. The same segment would display the highest CAGR of 12.5% from 2022 to 2031. Hospitals play a significant role in the delivery of hyper-personalized medicine, particularly in the administration and monitoring of personalized medicine.

North America to achieve the largest revenue by 2031

Based on region, the market in North America was the largest in 2021, accounting for more than two-fifths of the global hyper personalized medicine market and is expected to rule the roost during the forecast period. The rising healthcare spending, rising patient desire for individualized therapies, and breakthroughs in genomics and other sophisticated technologies are driving innovation in the sector. Asia-Pacific region, on the other hand, is expected to showcase noteworthy CAGR of 12.7% from 2022 to 2031, owing to rising healthcare spending, rising chronic illness prevalence, rising patient demand for tailored therapies, and breakthroughs in genomics and other sophisticated technologies.

Leading Market Players

  • Abbott,
  • Dako A/S
  • Illumina, Inc.
  • Exact Sciences Corporation
  • Decode Genetics, Inc.
  • QIAGEN, Exagen Inc.
  • GE Healthcare
  • ASURAGEN, INC.
  • Danaher Corporation (Cepheid, Inc.)

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

Biosimilars Market by Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others), by Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Vaccines Market by Technology Type (Recombinant & Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, and Other Vaccines), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, & Rubella {MMR}, Diphtheria, Pertussis, & Tetanus {DPT}, Polio, Hepatitis, and Other Indications), and End User (Pediatric, Adults, and Travelers): Global Opportunity Analysis and Industry Forecast, 2021--2031

Telemedicine Market by Application (Teleradiology, Telepsychiatry, Telepathology, Teledermatology, Telecardiology and Other Applications), Component (Software, Hardware and Services), and End User (Healthcare Providers, Payers, Healthcare Consumers and Other End Users): Global Opportunity Analysis and Industry Forecast, 2021-2030

Digital Therapeutics Market by Product (Software and Devices), Sales Channel (Business-to-Business and Business-to-Consumers), Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS), Disease Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID) and Others: Global Opportunity Analysis and Industry Forecast, 2022-2031

Remote Patient Monitoring Market by Condition (Congestive Heart Failure (CHF), Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Blood Pressure, Mental Health, Others), by Component (Devices, Software): Global Opportunity Analysis and Industry Forecast, 2021-2031

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

Modal title

Also from this source

Citrus Aurantium Extract Market to Reach $4,339.2 Million by 2027 in short term and $5,671.7 million by 2034 Globally, at 3.8% CAGR: Allied Market Research

Citrus Aurantium Extract Market to Reach $4,339.2 Million by 2027 in short term and $5,671.7 million by 2034 Globally, at 3.8% CAGR: Allied Market Research

Allied Market Research published a report, titled, "Citrus Aurantium Extract Market - Global Opportunity Analysis and Industry Forecast, 2025-2034",...

Speech-To-Text API Market to Reach $5 Billion by 2024 in the Short Term and $21 Billion by 2034 Globally, at 15.2% CAGR: Allied Market Research

Speech-To-Text API Market to Reach $5 Billion by 2024 in the Short Term and $21 Billion by 2034 Globally, at 15.2% CAGR: Allied Market Research

Allied Market Research published a report titled, "Speech-to-text API Market - Global Opportunity Analysis and Industry Forecast, 2024-2034," valued...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.